



Health Canada's Regulatory Review of Drugs and Devices (R2D2) was created out of a need to keep up with the rapidly changing healthcare system in Canada and to ensure all drugs and devices are safe, effective, and of the highest quality. How can you stay afloat with these new developments?



## KEY R2D2 TOPICS TO BE DISCUSSED AT THE DIA ANNUAL CANADIAN MEETING

### NEW PATHWAYS TO MARKET DRUGS



How can international work-sharing and the study of other regions' reviews/decisions help support drug submissions in Canada?

### OPPORTUNITIES WITH MEDICAL DEVICES



What are the post-market regulatory changes and how can we use real world evidence for new devices?

### CLINICAL TRIAL DESIGN



What ways can real-world data be utilized to enhance decision-making in the development of trial designs?

### PATIENT ENGAGEMENT




How do patient associations want to be included in conversations and how can we better engage them in the process of drug development?

### PERSONALIZED MEDICINE



Will using biomarkers or genetic testing in clinical trials aid in screening for new diseases?

### NEW TECHNOLOGY



Are we taking advantage of digital health, including artificial intelligence and the use of social media, to change the way patient needs are met?



### TRAVEL ONCE AND DOUBLE YOUR LEARNING!

Arrive on October 29 and attend DIA's *Canadian Pharmacovigilance and Risk Management Strategies Conference* at the same venue! Save \$150 when you register for both!

[FIND OUT MORE](#)